#1 Clinical Trials Search in Europe

Gindameran

This article discusses the ongoing clinical trials of Gindameran, a novel drug being investigated for the treatment of advanced melanoma. Gindameran is part of a combination therapy called BNT111, which includes other active substances such as vibosameran, enomimeran, and ontasameran. The trials aim to evaluate the effectiveness and safety of BNT111 in patients with stage III or IV melanoma who have not responded to previous treatments.

Table of Contents

What is GINDAMERAN?

GINDAMERAN is an innovative medical treatment being studied for advanced melanoma, a serious form of skin cancer. It is part of a drug called BNT111, which contains four active substances: gindameran, vibosameran, enomimeran, and ontasameran[1]. These substances are types of messenger RNA (mRNA), which are molecules that carry genetic instructions in our bodies.

How does GINDAMERAN work?

GINDAMERAN and its companion substances work by delivering specific genetic instructions to cells in your body. Each substance targets a different protein found in melanoma cells:

  • Gindameran targets a protein called NY-ESO-1
  • Vibosameran targets tyrosinase
  • Enomimeran targets MAGE-A3
  • Ontasameran targets TPTE

By introducing mRNA that codes for these proteins, BNT111 aims to stimulate your immune system to recognize and attack cancer cells that express these proteins[1].

What conditions does GINDAMERAN treat?

GINDAMERAN, as part of BNT111, is being studied for the treatment of advanced melanoma. Specifically, it’s being tested in patients with:

  • Stage III melanoma: This is when the cancer has spread to nearby lymph nodes but not to distant parts of the body.
  • Stage IV melanoma: This is when the cancer has spread to distant parts of the body, such as the lungs, liver, or brain[1].

The treatment is being studied in patients whose cancer has not responded to or has come back after previous treatments, particularly those involving drugs that target PD-1 or PD-L1 proteins[1].

Current Research on GINDAMERAN

GINDAMERAN is currently being studied in a Phase II clinical trial. This trial is testing BNT111 in combination with another drug called cemiplimab, as well as testing each drug separately. The main goals of this research are to:

  1. See how well the combination of BNT111 and cemiplimab works in shrinking tumors
  2. Check how well each drug works on its own
  3. Assess how safe the treatments are and how well patients tolerate them
  4. Measure how the treatments affect patients’ quality of life[1]

Who can participate in the GINDAMERAN trial?

The trial is open to adults (18 years or older) with advanced melanoma that meets specific criteria. Some key eligibility factors include:

  • Having stage III or IV melanoma that can’t be surgically removed
  • Having cancer that has grown or come back after treatment with certain immunotherapy drugs
  • Being in generally good health, with adequate organ function
  • Not having certain other medical conditions that could interfere with the treatment or its evaluation[1]

It’s important to note that there are many other specific criteria that determine eligibility. If you’re interested in participating, you should discuss this with your doctor to see if you might qualify.

Potential Benefits and Risks

As with any experimental treatment, there are potential benefits and risks to consider:

Potential benefits:

  • The treatment may help shrink tumors or slow cancer growth
  • Participants contribute to important medical research that could help future patients

Potential risks:

  • The treatment may not work as well as hoped
  • There may be side effects, some of which could be serious
  • Participating in the trial may require additional medical visits and procedures[1]

Conclusion

GINDAMERAN, as part of BNT111, represents a promising new approach to treating advanced melanoma. By harnessing the power of mRNA technology, it aims to stimulate the body’s own immune system to fight cancer. While the research is still ongoing, this treatment offers hope for patients with advanced melanoma who have not responded to other therapies. As always, patients should discuss their options with their healthcare providers to determine the best course of treatment for their individual situation.

Aspect Details
Drug Name Gindameran (part of BNT111)
Trial Phase Phase II
Condition Stage III or IV Melanoma
Patient Type Adults (≥18 years) with unresectable melanoma
Previous Treatment Disease progression after anti-PD-1/PD-L1 therapy
Main Objective Assess anti-tumor activity of BNT111 + cemiplimab
Primary Endpoint Objective Response Rate (ORR)
Treatment Duration Up to 104 weeks
Key Exclusions Pregnancy, significant cardiovascular disease, active infections
Safety Monitoring Adverse events, lab parameters, vital signs

FAQ

  • What is Gindameran and how does it work? Gindameran is one of the active substances in BNT111, a new treatment being tested for advanced melanoma. It works by delivering genetic instructions (mRNA) to produce a protein called NY-ESO-1, which helps the immune system recognize and fight cancer cells.
  • Who is eligible for the clinical trial involving Gindameran? The trial is for adults (18 years or older) with stage III or IV melanoma that has not responded to previous treatments, including anti-PD-1/PD-L1 therapy. Patients must have measurable disease and meet specific health criteria.
  • What are the main goals of the clinical trial? The primary goal is to measure the objective response rate (ORR) of patients treated with BNT111 and cemiplimab. Secondary goals include assessing the duration of response, disease control rate, time to response, progression-free survival, and overall survival.
  • Are there any side effects associated with Gindameran treatment? The trial will closely monitor for treatment-emergent adverse events (TEAEs), including serious or fatal events. Special attention will be given to immune-related adverse events (irAEs). The study will also track changes in laboratory parameters and vital signs.
  • How long does the treatment last in the clinical trial? The maximum treatment period in the trial is 104 weeks (2 years). However, the actual duration may vary depending on how patients respond to the treatment and any side effects they may experience.

Ongoing Clinical Trials on Gindameran

  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Spain

Glossary

  • Melanoma: A type of skin cancer that develops in cells called melanocytes, which produce melanin (the pigment that gives skin its color).
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Immune-related Adverse Events (irAEs): Side effects related to the immune system that can occur with certain cancer treatments.
  • mRNA: Messenger RNA, a type of genetic material that carries instructions for making proteins in cells.
  • ECOG PS: Eastern Cooperative Oncology Group Performance Status, a scale used to assess how a patient's disease affects their daily living abilities.
  • BRAF mutation: A specific change in the BRAF gene that can be found in some melanomas and affects treatment choices.
  • Unresectable: Unable to be removed completely through surgery.

References

  1. http://clinicaltrials.eu/trial/study-of-bnt111-and-cemiplimab-for-patients-with-advanced-melanoma-unresponsive-to-prior-treatments/